Navigation Links
Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
Date:10/18/2011

NATICK, Mass., Oct. 18, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for the treatment of benign bile duct strictures (narrowing or blockages).  This multi-center, prospective study enrolled 187 patients at 13 centers in 11 countries worldwide.  Lead Investigators in the study are Professor Jacques Deviere, M.D., Ph.D., of Hospital Erasme in Brussels, and Professor Guido Costamagna, M.D., of Policlinico A. Gemelli in Rome.

The study includes patients with bile duct strictures associated with post liver transplant anastomosis (connection of two structures), prior abdominal surgery such as cholecystectomy (gall bladder removal) and chronic pancreatitis (inflammation of the pancreas).  The WallFlex Biliary RX Fully Covered Stent will remain in patients five to 11 months depending on the nature of the stricture.  The trial will evaluate the removal of the stents from patients as well as the effectiveness of temporary stenting for long-term benign biliary stricture resolution.  Patients will be followed for five years after stent removal.  

"This is a key milestone for this important trial," said Professor Deviere.  "We look forward to the findings, which will determine the potential benefits of this stent as a less-invasive alternative to surgery in these types of patients and as an endoscopic treatment option that may require fewer ERCP(1) procedures than plastic stenting."

The WallFlex Biliary RX Stent is constructed of braided, Platinol™ (platinum-cored Nitinol) wire and features three key attributes:  radial force to help maintain duct patency and resist migration, flexibility to aid in conforming to tortuous anatomies, and full-length radiopacity to enhance stent visibility under fluoroscopy.
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Denovo Biopharma, LLC, ... late-stage oncology drug, from Eli Lilly and Company ... manufacture and commercialize enzastaurin globally, including transfer of ... information. Lilly developed enzastaurin in ... and Phase 3 clinical trials for diffuse large ...
(Date:9/16/2014)... Russia,s pharmaceutical market ... 2020 Strategy provides incentives for local producers to develop ... markets. These trends, however, were affected by recent developments ... and economic sanctions imposed on Russia ... Russia responded to the US and ...
(Date:9/16/2014)...   Evana Automation Specialists , a leading Systems ... systems, recently received a contract to provide a robotic ... Evana solution will help error-proof the process of assembling ... reduce labor. A catheter adapter, connector ... cell. The robot will pick the adapter, connector and ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Global Medicines for Russia 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3
... CardioGenics Holdings Inc. (CGNH.OB) announced today the transfer ... ultra sensitive magnetic beads for use in diagnostic ... beads business unit, which was previously operated out ... will now be operated exclusively out of Luxspheres, ...
... SAN FRANCISCO, June 22, 2011 Vista Partners ... Pharmaceuticals, Inc. (AMEX: ANX ) ("The Company" ... Ross Silver, Principal Analyst at Vista Partners stated, “ANX has ... that could serve multi-billion dollar markets and one candidate with ...
Cached Medicine Technology:CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 2CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary 3Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50 2
(Date:9/16/2014)... Dennis Thompson HealthDay ... -- A combination drug therapy aimed at opening the ... treatment for older adults with chronic obstructive pulmonary disease ... COPD patients who received a combination of ... to die or require hospitalization because of their breathing ...
(Date:9/16/2014)... Florida (PRWEB) September 16, 2014 Novatus, ... opened a new office in London, UK, and appointed ... accounts in Europe, the expansion will allow Novatus to ... of its European customers. , “Novatus ... market, and London is an ideal location to establish ...
(Date:9/16/2014)... One in five American men admits to using ... survey shows. A nationally representative study from ... is more prevalent than diabetes. This violence includes ... hitting, kicking, biting, choking, burning or threatening their ... Although abuse by high-profile professional athletes has recently ...
(Date:9/16/2014)... Boston University School of Medicine researcher Dr. Jeffrey ... University were recently awarded a five year, $5 ... Abuse for their project titled: Improving Physician Opioid ... Prescription opioids are the second most commonly abused ... deaths related to prescription opioids now exceed deaths ...
(Date:9/16/2014)... London, UK (PRWEB) September 16, 2014 ... paediatric clinical trials has risen considerably in line with ... USA, over 350 product labels include novel paediatric information ... safety review. In the European countries, there has been ... medicinal products from the submission of old or new ...
Breaking Medicine News(10 mins):Health News:Combo Therapy Best for COPD: Study 2Health News:Combo Therapy Best for COPD: Study 3Health News:Novatus Expands European Operations with a New Office in London 2Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 3
... Less Than One in Five Employers Offer Stand Alone Vision ... VSP(R) Vision Care launched the industry,s first ... it grow to more than 25,000 members nationwide. In a ... economy on health and vision care priorities and costs, VSP ...
... Company,s Portable 4.5kg "Lab in a Box" Allows for Rapid ... 9 DxNA announced today that it has submitted a ... its GeneSTAT(R) pathogen platform, for the detection of the H1N1 ... early availability of important diagnostic and therapeutics tools to diagnose, ...
... GeoFitness,s main goal has been to get Americans up ... and curriculum. Their ability to provide solutions to the ... has provided unprecedented growth. The name change to GeoMotion ... include 3 distinct product lines which can interact to offer ...
... , The Rx.com Electronic Pharmacy Record (EPR) to Integrate ... June 9 PDX and Rx.com have entered into ... which Rx.com manages for multiple chain and independent pharmacy ... single site with aggregated prescription data. The agreement enables ...
... NEW YORK, June 9 United Spinal Association ( ... Island ( www.IndependenceExpo.org ) , the region,s ... for individuals with disabilities and aging Americans. , ... 27th & Sunday, June 28th at the Suffolk Community College ...
... proprietary NeuroTrans(TM) technology , , NOVATO, Calif., June ... (OTC Bulletin Board: RPTP), today announced that it has ... (SWX: ROG.VX; RO.S, OTCQX: RHHBY) to evaluate therapeutic ... proprietary NeuroTrans(TM) BBB transporter platform. Under terms of the ...
Cached Medicine News:Health News:VSP's Individual Plan Thrives in a Starving Economy 2Health News:VSP's Individual Plan Thrives in a Starving Economy 3Health News:DxNA Submits its Rapid Detection Platform Test for H1N1 to FDA 2Health News:DxNA Submits its Rapid Detection Platform Test for H1N1 to FDA 3Health News:GeoFitness, Inc. is Now GeoMotion Group, an Innovative and Fast Growing Learning and Fitness Company for All Ages 2Health News:PDX-Rx.com Works With Microsoft HealthVault to Make Prescription Data Available to Patients 2Health News:PDX-Rx.com Works With Microsoft HealthVault to Make Prescription Data Available to Patients 3Health News:United Spinal Association Presents The 2009 Independence Expo: Improving Life for the Disabled and the Aging 2Health News:Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier 2Health News:Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier 3Health News:Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier 4Health News:Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier 5
... dual-monochromator, multi-detection microplate reader with a ... reading capability. Detection modalities include absorbance ... and have optical performance comparable to ... Endpoint, kinetic, spectrum and area-well scanning ...
... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...
... High Throughput Screening (HTS), Analyst HT ... HTS by sharing all the detection ... AD, fluorescence intensity, fluorescence polarization, time-resolved ... seamless integration into robotic environments, including ...
... Designed for Ultra High Throughput ... multimode assay detection performance. Allows for ... from assay development by sharing all ... and HT, fluorescence intensity, fluorescence polarization, ...
Medicine Products: